Lipe & Dalton grew its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 2.4% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 63,027 shares of the biopharmaceutical company’s stock after purchasing an additional 1,501 shares during the period. Gilead Sciences comprises 3.3% of Lipe & Dalton’s portfolio, making the stock its 9th largest holding. Lipe & Dalton’s holdings in Gilead Sciences were worth $4,866,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of GILD. Reilly Financial Advisors LLC grew its stake in shares of Gilead Sciences by 98.3% in the 3rd quarter. Reilly Financial Advisors LLC now owns 1,420 shares of the biopharmaceutical company’s stock valued at $110,000 after buying an additional 704 shares in the last quarter. Bay Colony Advisory Group Inc d b a Bay Colony Advisors bought a new stake in shares of Gilead Sciences in the 2nd quarter valued at approximately $132,000. Brand Asset Management Group Inc. bought a new stake in shares of Gilead Sciences in the 2nd quarter valued at approximately $139,000. TRUE Private Wealth Advisors bought a new stake in shares of Gilead Sciences in the 3rd quarter valued at approximately $174,000. Finally, Wealthsource Partners LLC bought a new stake in shares of Gilead Sciences in the 2nd quarter valued at approximately $206,000. Institutional investors own 78.09% of the company’s stock.

In other news, Director John C. Martin sold 50,000 shares of the stock in a transaction that occurred on Monday, October 1st. The stock was sold at an average price of $78.04, for a total value of $3,902,000.00. Following the completion of the sale, the director now directly owns 3,067,762 shares of the company’s stock, valued at $239,408,146.48. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders sold 150,000 shares of company stock valued at $11,087,500 over the last three months. 1.30% of the stock is owned by company insiders.

Shares of Gilead Sciences stock opened at $71.18 on Friday. The company has a market cap of $93.76 billion, a price-to-earnings ratio of 11.29, a P/E/G ratio of -2.81 and a beta of 1.01. The company has a debt-to-equity ratio of 1.09, a current ratio of 3.45 and a quick ratio of 3.39. Gilead Sciences, Inc. has a 12-month low of $64.27 and a 12-month high of $89.54.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Thursday, October 25th. The biopharmaceutical company reported $1.84 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.63 by $0.21. The firm had revenue of $5.60 billion during the quarter, compared to analysts’ expectations of $5.44 billion. Gilead Sciences had a return on equity of 39.32% and a net margin of 7.12%. During the same quarter in the prior year, the business earned $2.27 earnings per share. As a group, equities analysts predict that Gilead Sciences, Inc. will post 6.44 EPS for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, December 28th. Stockholders of record on Friday, December 14th will be given a $0.57 dividend. The ex-dividend date is Thursday, December 13th. This represents a $2.28 annualized dividend and a dividend yield of 3.20%. Gilead Sciences’s dividend payout ratio is 26.64%.

GILD has been the subject of several recent research reports. Zacks Investment Research raised Gilead Sciences from a “hold” rating to a “buy” rating and set a $86.00 price target for the company in a research note on Wednesday, July 18th. Robert W. Baird cut Gilead Sciences from an “outperform” rating to a “neutral” rating and set a $79.00 price target for the company. in a research note on Thursday, July 26th. Wells Fargo & Co boosted their price target on Gilead Sciences from $89.00 to $95.00 and gave the company an “outperform” rating in a research note on Thursday, July 26th. Morgan Stanley boosted their price target on Gilead Sciences from $81.00 to $85.00 and gave the company an “equal weight” rating in a research note on Thursday, July 26th. Finally, Mizuho set a $94.00 target price on Gilead Sciences and gave the stock a “buy” rating in a research report on Tuesday, July 31st. Twelve research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Gilead Sciences currently has a consensus rating of “Buy” and a consensus target price of $87.84.

TRADEMARK VIOLATION NOTICE: This article was originally reported by Daily Political and is the sole property of of Daily Political. If you are reading this article on another publication, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The correct version of this article can be accessed at https://www.dailypolitical.com/2018/11/10/lipe-dalton-has-4-87-million-stake-in-gilead-sciences-inc-gild.html.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.

Featured Story: Google Finance Portfolio

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.